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The Applicability of the Proposed IASLC Staging Revisions
to Small Cell Lung Cancer (SCLC) with Comparison to the
Current UICC 6th TNM Edition
Sai-Hong Ignatius Ou, MD, PhD,*†‡ and Jason A. Zell, DO, MPH*†‡
Background: We examined the impact of the proposed Internal
Association for the Study of Lung Cancer (IASLC) tumor, node,
metastasis (TNM) and stage grouping revisions on staging and
survival outcome of small cell lung cancer (SCLC).
Methods: A total of 10,660 SCLC patients from the California
Cancer Registry between 1991 to 2005 with complete TNM staging
were identified and reclassified according to the IASLC proposed
TNM revisions and new stage groupings. Surveillance Epidemiol-
ogy and End Results extent of disease codes were used to identify
various T4 and M descriptors. Cox proportional hazards regression
was used to identify prognostic factors.
Results: Survival was correlated with the current UICC6 and
IASLC proposed T descriptors. Patients without mediastinal lymph
node involvement (N 0–1) had superior survival compared to
patients with mediastinal lymph node involvement (N 2–3). The
IASLC proposed stage grouping results in better separation of
survival curves among early stage SCLC than the current Union
Internationale Centre le Cancer (UICC) 6 stage groupings by both
univariate and multivariate analyses. Pleural effusion (IASLC M1a)
in SCLC had survival similar to other IASLC M1a categories
(pericardial effusion, contralateral intrapulmonary metastasis) by
pairwise hazard ratio comparisons.
Conclusions: The IASLC proposed TNM staging changes result in
better separation of stage-specific SCLC survival curves than the
current UICC6 staging system. The new IASLC M1a descriptors
(pleural effusion, pericardial effusion, and contralateral/bilateral
intrapulmonary metastasis) adequately prognosticate SCLC patients
as having metastatic disease.
Key Words: Small cell lung cancer (SCLC), Epidemiology, TNM
staging system, Pleural effusion, Pericardial effusion, California
Cancer registry.
(J Thorac Oncol. 2009;4: 300–310)
Despite the gradual decline of small cell lung cancer(SCLC) incidence in the United States,1 it remains a
major cause of lung cancer deaths in the world.2 The prog-
nosis of SCLC remains extremely poor and therapeutic de-
velopment has lagged behind non-small cell lung cancer
(NSCLC). The tumor, node, metastasis (TNM) staging
system for lung cancer is also applicable to SCLC but
staging of SCLC has generally been functionally defined
and separated into limited disease and extensive disease
due to the fact that majority of the patients at the time of
diagnosis had locally advanced or metastatic disease that
are not amenable to surgery.3,4 Changes to the current TNM
lung cancer staging system have been proposed by the Inter-
nal Association for the Study of Lung Cancer (IASLC)
recently.5–8 The majority of the changes were made in the T5
and M7 descriptors and also the subsequent stage groupings.8
IASLC has compared these changes in SCLC to the current
6th edition AJCC TNM staging system.9 The proposed TNM
staging changes is better at discriminating SCLC patients into
nonoverlapping prognosis groups. However due to the lim-
ited number of SCLC patients with in the IASLC database,
the individual survival characteristics of the IASLC advanced
T and M descriptors were not examined and no data was
available on the prognosis of pericardial effusion.9 We have
previously performed validation studies of the IASLC pro-
posed TNM changes to both bronchioloalveolar carcinoma
(BAC)10 and non-BAC NSCLC11 using the California Cancer
Registry (CCR) database. In this article, we reported our
findings on the proposed changes in TNM staging system in
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SCLC and the individual survival characteristic of the ad-
vanced IASLC T and M descriptors.
PATIENTS AND METHODS
Objective
The primary outcome measure was to compare the
stage-specific overall survival (OS) of SCLC between current
UICC6 staging system and the proposed IASLC staging
modifications.
Population
A case-only analysis was conducted on SCLC patients
from CCR diagnosed between 1991 to 2005 who had complete
TNM staging data and follow-up data. Tumor site was ab-
stracted as previously described12 and both cytologically- or
histologically-confirmed SCLC cases were analyzed. Histology
codes (ICD-O-3: 8041-8044) were abstracted for SCLC. Histol-
ogy 8045 which coded for mixture of small and NSCLC was
eliminated from the final patient dataset.13,14 Patient demo-
graphic data were abstracted using Surveillance Epidemiology
and End Results (SEER) codes. The measurement of socioeco-
nomic status (SES) used in this analysis was a composite
measure using CCR and census data as previously de-
scribed.15,16 Radiation therapy and surgical techniques were
abstracted using SEER codes. Chemotherapy given during the
first course of therapy was ascertained using CCR codes.
The Extent of Disease (EOD) coding variable was ana-
lyzed for each patient and the T and M categories were recoded
according into the proposed revised IASLC staging system. This
maneuver allowed the comparison between the current and
IASLC TNM stage groupings. Specifically, EOD 65 which
codes for “separate tumor nodule(s) in the same lobe,” EOD 71
which codes for “heart, visceral pericardium,” EOD 72 which
codes for “malignant pleural effusions,” EOD 73 which codes
for “adjacent rib,” EOD 75 which codes for “sternum, verte-
bra(e) skeletal muscle, skin of chest,” EOD 77 which codes for
“separate tumor nodule(s) in separate lobe,” EOD 78 which
codes for “separate tumor nodule(s) in contralateral lung” and
EOD 79 which codes for “(malignant) pericardial effusion”
were used to identify the various T and M descriptors that were
reclassified by IASLC. Finally, patients with unknown EOD,
incomplete nodal (NX) or metastasis (MX) data were eliminated
from the final patient dataset.
Restaging Patients According to the IASLC
Revision for T4 and M Descriptors
Based on proposed IASLC revisions and stage group-
ing, the T4 descriptor for additional tumor nodules in the
same lobe was changed to T3. We restaged these patients
(T3N0M0) as stage IIB, patients with T3N1–2M0 as IIIA,
and patients with T3N3M0 remained staged IIIB. The T4
descriptor for pleural dissemination (malignant pleural effu-
sion/pleural nodules) or malignant pericardial effusion was
changed to M1a in the IASLC staging changes and we
restaged these patients as stage IVA. Patients with “ipsilateral
intrapulmonary nodules” were changed from M to T4 in the
IASLC changes. These IASLC T4 patients were restaged
according to their nodal status with both the current UICC6
and proposed IASLC stage grouping. Patients with contralat-
eral intrapulmonary nodules remained as having metastatic
disease (M) with a new M1a designation and grouped as stage
IVA. Even though the proposed IASLC staging does not
officially separate stage IV into stage IVA and stage IVB, we
grouped stage IV patients into these two groups according to
M1a and M1b to facilitate Cox proportional regression anal-
ysis. We restaged all T4N0–1M0 patients as stage IIIA
(which represents a major change in the current proposed
IASLC stage grouping).8
All early stage tumors were also reclassified according
to tumor sizes and EOD codes and their stage grouping
according to the UICC6 and IASLC proposed changes to
allow for the Cox proportional regression analysis.
Statistical Analyses
Comparisons of demographic, clinical, and pathologic
variables were made for SCLC patients, using Pearson 2
statistic or Fisher’s exact test for nominal variables and
Student t test for continuous variables. Analysis of variance
with Tukey’s posthoc test was used for multiple comparisons
of continuous variables. Univariate survival rate analyses
were estimated using the Kaplan and Meier method, with
comparisons made between groups by the log-rank test. Cox
proportional hazards modeling using time since diagnosis
were performed. Each variable in the model was coded using
dummy variables. All statistical analyses were conducted
using SAS 9.1 statistical software (SAS Institute, Inc., Cary,
NC). Statistical significance was assumed for a two-tailed p
value less than 0.05.
Ethical Considerations
This research study was approved by the University of
California Irvine Institutional Review Board (Institutional
Review Board #2004-3971 and #2007-6078).
RESULTS
Patients and Tumor Demographics
Incident cases of SCLC (17,164) were identified be-
tween 1991 and 2005 in CCR. 6303 cases where EOD, NX,
or MX were unknown were excluded. An additional 201
patients with combined small cell/NSCLC histology were
excluded. A total of 10,660 patients comprised the final study
population for this report used to generate the comparison of
the hazards ratio of the Union Internationale Centre le Cancer
(UICC) 6 and IASLC stages by Cox proportional hazards
regression analysis. The median age of diagnosis of the whole
cohort of patients was 67.2 years (95% Confidence interval
CI: 50–82 years). The median follow-up time was 7 months
for all patients (95% CI: 0–50 months).
T Category
Increasing clinical T category using the UICC6 TNM
staging system (Figure 1A) or the IASLC proposed changes
to the TNM system (Figure 1B) resulted in progressively
poorer survival in patients who did not have metastatic (M0)
involvement. The p value for the ordered log-rank test is less
than 0.0001 for both UICC6 and IASLC T categories. The 1-,
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2- and 5-year survival rates, and median OS of UICC6 T
categories are shown Table 1. The corresponding survival
numbers among the IASLC T categories were shown in Table
2. Pairwise comparisons of hazard ratio (HR) for survival
between sequential UICC6 T category were all statistically
significant similar to what was reported by IASLC.9 How-
ever, similar pairwise comparisons between IASLC T cate-
gories did not show statistical significance between T3 versus
T2 (p  0.0829) though the survival of T3 was numerically
worse than T2. The increase in the number of patients with
IASLC T3 category were due to the redistribution of UICC6
T2 patients with tumor 7 cm and UICC6 T4 patients with
satellite nodules into the IASLC T3 category.
N Category
Similar to T category, increasing N category was asso-
ciated with progressively worse survival (Figure 2). The
FIGURE 2. Overall survival curves of the four UICC6 N cat-
egories (T1–4 M0).
TABLE 1. Overall Comparison for Clinical Category UICC6 T1–4 (Any N) M0 Small Cell Lung Cancer, California Cancer
Registry Database (1991–2005)
T
Category n Deaths
1-yr
Survival (%)
2-yr
Survival (%)
5-yr
Survival (%)
Median
OS (mo) Comparison HR 95% CI p
T1 706 533 69.1 40.7 21.1 19
T2 967 842 56.4 25.9 12.2 14 T2 vs. T1 1.432 1.286–1.595 0.0001
T3 144 131 47.2 20.1 8.9 12 T3 vs. T2 1.226 1.019–1.474 0.0305
T4 2507 2345 35.4 14.7 5.9 9 T4 vs. T3 1.263 1.060–1.507 0.0092
HR, hazard ratio; OS, overall survival; CI, confidence interval.
TABLE 2. Overall Comparison for Clinical Category IASLC T1–4 (Any N) M0 Small Cell Lung Cancer, California Cancer
Registry Database (1991–2005)
T
Category n Deaths
1-yr
Survival (%)
2-yr
Survival (%)
5-yr
Survival (%)
Median
OS (mo) Comparison HR 95% CI p
T1 706 533 69.1 40.7 21.1 19
T2 857 743 56.4 26.3 12.6 14 T2 vs. T1 1.416 1.268–1.581 0.0001
T3 316 284 53.2 22.2 9.5 13 T3 vs. T2 1.129 0.984–1.294 0.0829
T4 1484 1371 41.1 17.6 7.0 10 T4 vs. T3 1.233 1.085–1.401 0.0013
HR, hazard ratio; OS, overall survival; CI, confidence interval; IASLC, Internal Association for the Study of Lung Cancer.
FIGURE 1. A, Overall survival curves of the four UICC6 T
categories (N 0–3 M0). B, Overall survival curves of the four
reclassified Internal Association for the Study of Lung Cancer
(IASLC) T categories (N 0–3 M0).
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p value for the ordered log-rank test is less than 0.0001. The
1-, 2-, and 5-year survival rates, and median overall OS of the
N categories were shown in Table 3. Pairwise comparisons of
the HR between sequential N categories revealed nonsignifi-
cance between N1 versus N0 (p 0.8187) which was similar
to the findings reported by IASLC.9 Survival curves of each
IASLC T category according to the N categories were shown
in Figures 3A–D with the corresponding survival numbers
shown in Table 4. Increasing N category portends poorer
survival within each IASLC T category except IASLC T4
category (p  0.1237).
Survival According to TNM Stage
All 10,660 SCLC patients in this dataset were classified
to according to the UICC6 and IASLC stage groupings. The
changes in the number of patients from UICC6 to IASLC
FIGURE 3. A, Overall survival curves of Internal Association for the Study of Lung Cancer (IASLC) T1 category according to
individual N category (N 0–3). B, Overall survival curves of IASLC T2 category according to individual N category (N 0–3). C,
Overall survival curves of IASLC T3 category according to individual N category (N 0–3). D, Overall survival curves of IASLC
T4 category according to individual N category (N 0–3).
TABLE 3. Overall Comparison for Clinical Category N0–N3 (Any T) M0 Small Cell Lung Cancer, California Cancer Registry
Database (1991–2005)
N
Category n Deaths
1-yr
Survival (%)
2-yr
Survival (%)
5-yr
Survival (%)
Median
OS (mo) Comparison HR 95% CI p
N0 902 734 59.3 32.8 18.2 16
N1 256 210 63.6 31.0 17.2 17 N1 vs. N0 0.982 0.843–1.145 0.8187
N2 2732 2519 41.5 17.9 7.2 10 N2 vs. N1 1.602 1.391–1.844 0.0001
N3 434 408 36.4 16.2 5.2 9 N3 vs. N2 1.113 1.003–1.236 0.0444
HR, hazard ratio; OS, overall survival; CI, confidence interval.
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within each stage were shown in Table 5. Survival curves
according to the UICC6 and IASLC stage groupings were
shown in Figures 4A, B respectively. The corresponding 1-,
2-, 5-year survival rates, and median OS numbers were
shown in Table 6. As shown in Table 6, the median OS of
UICC6 stage IB (17 months) and UICC6 stage IIA (22
months) were reversed whereas the median OS of IASLC
stage IB (18.5 months) and IASLC stage IIA (19 months)
were essentially superimposed. Thus the IASLC staging sys-
tem allowed a better separation of stage IB and IIA SCLC.
Pairwise comparisons of HR for OS between each successive
individual UICC6 and IASLC stage were shown in Table 7.
The comparison between UICC6 stage IIA versus stage IB
were not statistically significant but was better than reported
by IASLC where the survival of UICC6 stage IIA was
actually statistically significant better than UICC stage IB.9
Comparisons of OS of our CCR database using the UICC6
and IASLC stage groupings with the IASLC database and
IASLC SEER validation set were shown in Table 8. Finally
the HRs of the various stages of UICC6 and IASLC staging
system with stage IA as a referent were determined with Cox
proportional hazards analyses after adjusting for multiple
independent prognostic factors including age at diagnosis,
gender, ethnicity, socioeconomic status, marital status, sur-
gery, radiation, and chemotherapy and were shown in Table
9. The HR for OS for UICC6 stage IIA was not statistically
significant different from UICC6 stage IA (HR 1.305; 95%
CI: 0.970–1.756; p  0.0782) while IASLC stage IB was
marginally not statistically than IASLC stage IA (HR 
1.219; 95% CI: 0.996–1.492; p  0.05498). HRs for the
subsequent IASLC stages (beyond stage IB) were statistically
significant worse than IASLC stage IA indicating IASLC
staging groupings is an improvement over the UICC6. Our
aggregate results demonstrated an improved survival fit for
the proposed IASLC changes as compared with the current
UICC6 staging system for SCLC. The complete Cox propor-
tional hazards analysis was shown in supplemental Table S1
for UICC6 stage grouping and in supplemental Table S2 for
IASLC stage grouping.
TABLE 4. Overall Survival of IASLC T Descriptors According to Nodal Status (N 0–3)
Nodal Status Total Deaths
1-yr Survival
Estimate (%)
2-yr Survival
Estimate (%)
5-yr Survival
Estimate (%)
Median
OS (mo) p
IASLC T1
(n  706)
0.0001
N0 288 206 73.6 47.6 28.2 23
N1 76 56 80.3 43.4 25.9 22
N2 310 262 65.5 35.5 14.7 17
N3 32 29 37.5 21.9 7.8 11
IASLC T2
(n  857)
0.0001
N0 286 225 65.0 33.9 20.7 17
N1 73 61 60.3 28.8 16.3 17
N2 465 426 52.0 21.6 7.5 13
N3 33 31 36.4 21.2 6.1 12
IASLC T3
(n  316)
0.0428
N0 65 55 64.6 32.3 15.0 15
N1 32 28 59.4 25.0 12.5 15.5
N2 191 174 50.8 19.4 8.1 13
N3 28 27 35.7 14.3 3.6 9
IASLC T4
(n  1484)
0.1237
N0 166 154 45.2 19.3 7.0 11
N1 58 49 53.1 24.8 12.8 14
N2 1059 981 39.5 16.6 6.9 10
N3 201 187 42.4 19.7 5.6 10
IASLC, Internal Association for the Study of Lung Cancer; OS, overall survival.
TABLE 5. Reclassifications of all SCLC Patients from the
UICC6 Stage Grouping to IASLC Stage Grouping
UICC6 Stage
Grouping
(Total)
IASLC Stage Grouping
IA IB IIA IIB IIIA IIIB IVAa IVBa
IA (288) 288 — — — — — — —
IB (321) — 230 56 35 — — — —
IIA (76) — — 76 — — — — —
IIB (109) — — 58 36 15 — — —
IIIA (937) — — — — 919 18 — —
IIIB (2593) — — — 9 190 768 1626 —
IV (6336) — — — — 13 81 276 5966
IASLC, Internal Association for the Study of Lung Cancer; SCLC, small cell lung
cancer.
a IASLC does not separate stage IV into Stage IVa and Stage IVb.
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Overall Survival of the Seven Subtypes of UICC6
T4 and M Descriptors that Were Reclassified by
IASLC Proposed Staging Changes
The 1-, 2-, and 5-year survival estimates, and median
OS of UICC6 T4 patients due to additional nodules in the
same lobe, UICC6 T4 patients due to malignant pleural
dissemination, UICC6 T4 patients due to malignant pericar-
dial effusion, patients with UICC6 T4 invasion, UICC6 M
patients due to ipsilateral intrapulmonary nodules, UICC6 M
patients due to contralateral intrapulmonary nodules, and
UICC6 M patients due to distant metastasis were listed in
Table 10. The Kaplan-Mierer survival curves of these seven
T4 and M categories were plotted in Figure 5. Patients with
contralateral intrapulmonary metastasis, malignant pleural
dissemination, or pericardial effusions had similar dismal
survival. In contrast with NSCLC where patients with addi-
tional/satellite nodules had significantly better survival10,11
partially due to a high rate of surgical resection,17,18 SCLC
patients with T4 additional nodules in the same lobe had
better but not marked improved survival over patients with
other advanced T categories. Of the 89 SCLC patients with TA
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FIGURE 4. A, Overall survival curves of individual stage ac-
cording to the UICC6 stage grouping. B, Overall survival
curves of individual stage according to the Internal Associa-
tion for the Study of Lung Cancer (IASLC) stage grouping.
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TABLE 7. Pairwise Comparison of Hazard Ratio of UICC and IASLC Stages
Hazard Ratio p
Comparisons UICC6 IASLC UICC6 IASLC
IB vs. IA 1.339 (1.113–1.609) 1.279 (1.047–1.563) 0.0019 0.0161
IIA vs. IB 0.771 (0.577–1.030) 0.987 (0.794–1.227) 0.0783 0.9070
IIB vs. IIA 1.576 (1.129–2.198) 1.241 (0.931–1.654) 0.0074 0.1401
IIIA vs. IIB 1.121 (0.905–1.389) 1.132 (0.885–1.447) 0.2956 0.3238
IIIB vs. IIIA 1.462 (1.351–1.582) 1.195 (1.089–1.311) 0.0001 0.0002
IV vs. IIIB 1.606 (1.531–1.684) — 0.0001 —
IVA vs. IIIB — 1.505 (1.384–1.637) — 0.0001
IVB vs. IVA — 1.367 (1.297–1.442) — 0.0001
IASLC, Internal Association for the Study of Lung Cancer.
TABLE 8. Comparison of Median Overall Survival of SCLC Patients Between
CCR Database, IASLC Database, and IASLC SEER Validation Set
Median Overall Survival
CCR Database IASLC Databasea IASLC SEER
Validation Seta
IASLCUICC6 IASLC UICC6 IASLC
Stage IA 23 mo 23 mo 31 mo 31 mo 26 mo
Stage IB 17 mo 18.5 mo 26 mo 35 mo 21 mo
Stage IIA 22 mo 19 mo NR 68 mo 15 mo
Stage IIB 15 mo 15 mo 18 mo 17 mo 12 mo
Stage IIIA 14 mo 14 mo 13 mo 13 mo 13 mo
Stage IIIB 9 mo 11 mo 12 mo 12 mo 11 mo
Stage IV 5 mo — 8 mo 8 mo 6 mo
Stage IVAb 7 mo
Stage IVBb 5 mo
a Data from Shepherd FA, Crowley J, Houtte PV, et al. The International Association for the Study of Lung
Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the
forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol
2007;2:1067–1077.
b There is no official stage IVA (M1a) and stage IVB (M1b) as proposed by IASLC.
IASLC, Internal Association for the Study of Lung Cancer; SCLC, small cell lung cancer; SEER,
Surveillance Epidemiology and End Results; CCR, California Cancer Registry.
TABLE 9. Comparison of Hazard Ratio of Individual Stage According to UICC6 and IASLC Proposed
Staging System Using Cox Proportional Hazards Regression Analysis
UICC6 IASLC
Hazard
Ratioa
95% Confidence
Interval p
Hazard
Ratioa
95% Confidence
Interval p
Stage Stage
Stage IA 1.00 Stage IA 1.00
Stage IB 1.252 (1.039–1.509) 0.0182 Stage IB 1.219 (0.996–1.492) 0.0548
Stage IIA 1.305 (0.970–1.756) 0.0782 Stage IIA 1.490 (1.205–1.842) 0.0002
Stage IIB 1.924 (1.504–2.460) 0.0001 Stage IIB 1.540 (1.166–2.033) 0.0023
Stage IIIA 1.813 (1.543–2.130) 0.0001 Stage IIIA 1.858 (1.584–2.178) 0.0001
Stage IIIB 2.716 (2.331–3.165) 0.0001 Stage IIIB 2.369 (2.010–2.792) 0.0001
Stage IV 3.992 (3.433–4.641) 0.0001 Stage IVAb 3.095 (2.649–3.615) 0.0001
Stage IVBb 4.251 (3.653–4.947) 0.0001
a Adjusted for age, gender, ethnicity, socioeconomic status, marital status, surgery, radiation and chemotherapy. The complete list of variables
included in the Cox proportional hazards regression analysis and the hazard ratios were listed in supplemental Table 1 (UICC6) and Table 2 (IASLC).
b There is no official stage IVA (M1a) or stage IVB (M1b) as currently proposed by IASLC.
IASLC, Internal Association for the Study of Lung Cancer.
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“satellite nodules” in our dataset, only two patients under-
went surgical intervention (both lobectomy). We also per-
formed pairwise HR comparisons between the seven ad-
vanced T and M descriptors (Table 11). Of note, there was no
significant difference in OS among patients with contralateral
intrapulmonary metastasis (IASLC M1a), malignant pleural
effusion (IASLC M1a), or malignant pericardial effusion
(IASLC M1a). Furthermore, all IASLC M1a patients had
significant OS advantage over IASLC M1b patients indicat-
ing all 3 M1a categories in the IASLC proposed staging
changes were applicable to SCLC. Due to the limited number
of patients (n  94), it is difficult to determine the prognostic
significance of patients with ipsilateral intrapulmonary me-
tastasis (IASLC T4) as the survival of these patients is
significant better patients with malignant pleural effusion
(M1a) but worse than patients with T4 invasion (IASLC T4).
DISCUSSION
The current IASLC proposed changes to the TNM
descriptors and stage grouping represents a major and signif-
icant change to the staging of lung cancer.19 IASLC has
applied these changes to SCLC. Due to limited number of
SCLC patients with complete TNM staging data in the
IASLC database, changes in the prognostic significance for
the individual advanced T and M descriptor were not indi-
vidually examined.9 In this report, we adopted all the pro-
posed changes to the T4 and M descriptors and reclassified
SCLC patients according to the new IASLC stage grouping
and investigated the applicability of these staging changes to
SCLC with comparison to the current UICC6 staging system.
Our results showed that the T category whether it is
according to the UICC6 or IASLC staging system can dif-
ferentiate survival of nonmetastatic (M0) SCLC patients very
well regardless of nodal status. There was no change to the N
category by IASLC6 and we showed that with exception to
pairwise comparison between N1 and N0 the current N
category can differentiate survival of T1–3 M0 patients very
well except T4 in our study in agreement with the IASLC
report.9 Regarding stage groupings, our results showed that
IASLC stage grouping is able to better differentiate OS of
earlier stage SCLC than the current UICC6 stage grouping.
The OS curves were reversed between the UICC6 stage IB
and UICC6 IIA similar to the IASLC report.9 However, there
was superimposing of survival curves for IASLC stage IB
and IASLC stage IIA. Inoue et al. have also reported that
stage IIA SCLC had better survival than stage IB SCLC in
their surgical series and that T descriptor is a stronger
prognostic factor than N descriptor for resectable SCLC.20
Our results and that of IASLC9 also showed that the T
descriptor (whether according to UICC6 or IASLC) is better
at prognosticating early stage SCLC patients than the N
descriptor.
Finally, we reported on the survival characteristics of
the seven individual advanced T and M descriptors that
would be changed as proposed by IASLC. The absolute OS
differences among the seven descriptors are not as widely
separated as seen in BAC10 and non-BAC NSCLC11
though the difference remained statistically significant
(p  0.0001). Our report did show that there were no OS
differences among patients with contralateral intrapulmo-
FIGURE 5. Overall survival curves of the seven advanced T
and M descriptors reclassified according to the changes pro-
posed by Internal Association for the Study of Lung Cancer
(IASLC).
TABLE 10. Survival Characteristics of SCLC Patients with the Seven Subtypes of UICC6 T4 and M Descriptors that Undergo
Revisions as Proposed by IASLC
UICC6 T4 and M Descriptors (IASLC
Proposed Changes) Total Deaths
1-yr
Survival
Estimate
(%)
2-yr
Survival
Estimate
(%)
5-yr
Survival
Estimate
(%)
Median
Overall
Survival (mo)
T4-“satellite nodules” (IASLC 3 T3) 89 78 53.9 23.6 11.6 14
T4-“invasion” (IASLC 3 T4 no change) 878 789 47.9 22.6 9.4 12
M-“ipsilateral intra-pulmonary nodules”
(IASLC 3 T4)
94 91 36.2 14.9 1.9 10.5
M-“contralateral intra-pulmonary nodules”
(IASLC 3 M1a)
276 264 32.9 12.7 3.3 8
T4-“pleural dissemination” (IASLC 3 M1a) 1518 1456 27.3 9.7 3.6 7
T4-“pericardial effusion” (IASLC 3 M1a) 108 102 33.3 16.7 4.8 7
M-“distant metastasis” (IASLC 3 M1b) 5966 5883 16.6 3.8 1.0 5
IASLC, Internal Association for the Study of Lung Cancer; SCLC, small cell lung cancer.
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nary metastasis, pleural effusion, or pericardial effusion by
pairwise HR comparisons and their OS was significantly
better than patients with distant metastasis. These results
lend support for three categories to be classified as M1a
while distant metastasis is classified as M1b in SCLC.
IASLC reported that patients with pleural effusion had
survival intermediate between limited disease and exten-
sive disease9 and this report is in agreement for SCLC
patients with malignant pleural effusion to be classified as
having distant metastasis similar to NSCLC patients.
We were less successful in prognosticating the IASLC
T4 category for SCLC as patients with “T4 invasion” (IASLC
T4) had OS similar to the patients with “satellite lesions in the
same lobe” (IASLC T3) by pairwise HR comparison even
though there was an absolute 2 months difference in OS
favoring patients with “satellite lesions” (IASLC T3). On the
contrary patients with “ipsilateral intrapulmonary metastasis”
(IASLC T4) had survival significantly worse than patients
with T4 invasion by pairwise HR comparison and an absolute
1.5 months shortened OS (Table 5). One of the likely expla-
nations is the small number of SCLC patients with “addi-
tional nodules in the same lobe” (n  89) and “ipsilateral
intrapulmonary metastasis” (n  94) and even smaller num-
bers of patients who underwent surgical intervention. Out of
the 89 SCLC patients with satellite lesions in the same lobe,
only two patients underwent surgical intervention (both lo-
bectomy and both with N1 disease) and represented a signif-
icant lower proportion of patients than patients with BAC17 or
non-BAC NSCLC18 who underwent resection. It can be
hypothesized that by adopting the IASLC TNM staging
changes for SCLC, more patients will likely undergo ana-
tomic resection in the future and the prognostic significance
of between T3 and T4 will be more apparent. In summary,
this report revealed that the IASLC TNM staging changes to
SCLC is better in prognosticating SCLC patients than the
current UICC6.
This study is retrospective in nature and thus carried
with it limitations of population-based studies. There was no
uniform standard protocol on how the lung cancer patients
were staged (i.e., lymph node staging or systemic staging),
thus all the CCR registry patients were analyzed using “best
available stage” based on combined clinical and pathologic
staging data. Secondly, there was no centralized review of
pathologic specimens as the definition of small cell lung
carcinoma has evolved throughout the years;14 however, we
have excluded patients with tumor histology that included
both small cell/non-small cell carcinoma. The accuracy of
NSCLC histologic reporting in SEER has been reported
favorably in comparison to independent review.21 There is no
uniform protocol on how treatment (surgery, radiation or
chemotherapy) was given. Despite these limitations, our pair-
wise comparison of survival characteristics of advanced
NSCLC of our CCR validation set is very similar to the
IASLC SEER validation set. Moreover we have included
TABLE 11. Pairwise Comparison of Hazard Ratio (HR) of Death Among the Seven
Advanced T and M Descriptors that Undergo Staging Change as Proposed by IASLC
Pairwise Comparisons HR
95% Confidence
Interval p
T4 “satellite lesion” (IASLC T3) (n  89)
vs. Ipsilateral intrapulmonary nodules (IASLC T4) 0.708 0.522–0.960 0.0261
vs. T4 “invasion” (IASLC T4) 0.906 0.718–1.143 0.4038
T4 “invasion” (IASLC T4) (n  878)
vs. T4 “satellite lesion” (IASLC T3) 1.104 0.875–1.393 0.4038
vs. Ipsilateral intrapulmonary nodules (IASLC T4) 0.789 0.635–0.980 0.0324
vs. Contralateral intrapulmonary nodules (IASLC M1a) 0.658 0.572–0.756 0.0001
vs. Malignant pleural effusion (IASLC M1a) 0.615 0.563–0.671 0.0001
vs. Malignant pericardial effusion (IASLC M1a) 0.684 0.556–0.840 0.0003
Ipsilateral intra-pulmonary nodules (IASLC T4) (n  94)
vs. T4 invasion (IASLC T4) 1.268 1.020–1.575 0.0324
vs. Contralateral intrapulmonary nodules (IASLC M1a) 0.840 0.662–1.066 0.1519
vs. Malignant pleural effusion (IASLC M1a) 0.773 0.625–0.956 0.0173
vs. Malignant pericardial effusion (IASLC M1a) 0.881 0.663–1.169 0.3795
Malignant pericardial effusion (IASLC M1a) (n  108)
vs. Malignant pleural effusion (IASLC M1a) 0.888 0.727–1.086 0.2487
vs. Contralateral intrapulmonary nodules (IASLC M1a) 0.957 0.761–1.203 0.7038
vs. Distant metastasis (IASLC M1b) 0.660 0.542–0.803 0.0001
Malignant pleural effusion (IASLC M1a) (n  1518)
vs. Contralateral intrapulmonary nodules (IASLC M1a) 1.087 0.954–1.240 0.2103
vs. Distant metastasis (M1b) 0.746 0.704–0.791 0.0001
Contralateral intrapulmonary nodules (IASLC M1a)
(n  276)
vs. Distant metastasis (M1b) 0.681 0.601–0.770 0.0001
HR, hazard ratio; IASLC, Internal Association for the Study of Lung Cancer.
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many independent prognostic factors into the Cox propor-
tional regression analysis. We believe this report will provide
further support to the use of TNM staging system in SCLC
especially with the new IASLC staging system.
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TABLE S1. Cox Multivariate Analysis of the UICC6 Staging
System for SCLC
UICC6
Hazards
Ratio
95% Confidence
Interval p
Stage
Stage IA 1.000
Stage IB 1.252 (1.039–1.509) 0.0182
Stage IIA 1.305 (0.970–1.756) 0.0782
Stage IIB 1.924 (1.504–2.460) 0.0001
Stage IIIA 1.813 (1.543–2.130) 0.0001
Stage IIIB 2.716 (2.331–3.165) 0.0001
Stage IV 3.992 (3.433–4.641) 0.0001
Age 1.014 (1.012–1.016) 0.0001
Gender
Male 1.000
Female 0.875 (0.840–0.911) 0.0001
Ethnicity
Caucasian 1.000
African American 0.937 (0.861–1.019) 0.1306
Hispanic 0.989 (0.920–1.063) 0.7572
Chinese 0.797 (0.664–0.957) 0.0152
Non-Chinese Asian 0.844 (0.758–0.939) 0.0019
Other 0.933 (0.607–1.433) 0.7501
Marital status
Married 1.00
Unmarried 1.105 (1.060–1.151) 0.0001
Unknown 1.150 (0.981–1.347) 0.0852
Socioeconomic status 0.969 (0.955–0.984) 0.0001
Surgery
No 1.000
Yes 0.423 (0.367–0.488) 0.0001
Radiation
No 1.000
Yes 0.707 (0.678–0.737) 0.0001
Chemotherapy
No 1.000
Yes 0.377 (0.359–0.395) 0.0001
SCLC, small cell lung cancer.
TABLE S2. Cox Multivariate Analysis of the IASLC Staging
System for SCLC
UICC6
Hazards
Ratio
95% Confidence
Interval p
Stage
Stage IA 1.000 (0.996–1.492)
Stage IB 1.219 (1.205–1.842) 0.0548
Stage IIA 1.490 (1.166–2.033) 0.0002
Stage IIB 1.540 (1.584–2.178) 0.0023
Stage IIIA 1.858 (2.010–2.792) 0.0001
Stage IIIB 2.369 (2.649–3.615) 0.0001
Stage IVA 3.095 (3.653–4.947) 0.0001
Stage IVB 4.251 0.0001
Age 1.014 (1.012–1.016) 0.0001
Gender
Male 1.000 0.0001
Female 0.877 (0.842–0.913)
Ethnicity
Caucasian 1.000
African American 0.939 (0.863–1.021) 0.1425
Hispanic 1.002 (0.932–1.077) 0.9583
Chinese 0.823 (0.685–0.988) 0.0364
Non-Chinese Asian 0.843 (0.757–0.938) 0.0017
Other 0.912 (0.593–1.402) 0.6752
Marital status
Married 1.00
Unmarried 1.101 (1.056–1.148) 0.0001
Unknown 1.185 (1.011–1.389) 0.0359
Socioeconomic status 0.967 (0.952–0.982) 0.0001
Surgery
No 1.000 0.0001
Yes 0.445 (0.386–0.513)
Radiation
No 1.000 0.0001
Yes 0.722 (0.692–0.753)
Chemotherapy
No 1.000 0.0001
Yes 0.379 (0.361–0.397)
SCLC, small cell lung cancer; IASLC, Internal Association for the Study of Lung
Cancer.
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